Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/39106
Title: | Open-label, dose escalation, phase I/II study to assess safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-programmed death-1 (PD-1) treatment in patients with non-small cell lung cancer (NSCLC) | Authors: | Vansteenkiste, J. F. Demedts, I. Pons-Tostivint, E. Biesma, B. Borm, F. Colinet, B. CUPPENS, Kristof Derijcke, S. Greillier, L. Juergens, J. Moro-Sibilot, D. Perol, M. Sebastian, M. Skrzypski, M. Theelen, W. Van De Kerkhove, C. Collodoro, M. Plumas, J. Debruyne, C. Sibille, A. |
Issue Date: | 2022 | Publisher: | ELSEVIER | Source: | ANNALS OF ONCOLOGY, 33 (7) , p. S1086 (Art N° 1176P) | Document URI: | http://hdl.handle.net/1942/39106 | ISSN: | 0923-7534 | e-ISSN: | 1569-8041 | DOI: | 10.1016/j.annonc.2022.07.1299 | ISI #: | 000866211601438 | Category: | M | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
1176PO~1.PDF Restricted Access | Published version | 85.34 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.